Neuroinflammation and glycosylation-related cerebrospinal fluid proteins for predicting functional decline in amyotrophic lateral sclerosis: a proteomic study
Authors:
Open Access
- 18 November 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1418320
Abstract
Background: The rate of disease progression varies widely among patients with amyotrophic lateral sclerosis (ALS). Prognostic assessment using biomarkers is highly anticipated to improve clinical trial design. We aimed to explore the cerebrospinal fluid (CSF) for prognostic biomarkers to predict future functional decline in patients with ALS.Methods: We collected CSF samples from 64 patients with ALS and 25 disease controls. The prospective progression rate was calculated using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) at CSF collection and in 6 months. The ALS patients were classified into slow, intermediate, and fast progression groups. We performed comprehensive proteomic analyses of the CSF samples. Factors with significant changes between slow and fast progression groups were investigated via receiver operating characteristic curve analyses. Moreover, the correlation of the CSF factors with progression rate was evaluated by multiple regression analyses.Results: In total, 26 proteins changed significantly (p < 0.05 and q < 0.10), with levels varying within a large dynamic range (fold change of >1.5 or < 0.5). A receiver operating characteristic curve analyses showed that the following proteins showed high discrimination power between slow and fast progression groups: glycoprotein non-metastatic melanoma protein B (GPNMB; area under the curve [AUC], 0.88), glial fibrillary acidic protein (AUC, 0.81), glypican-1 (GPC1; AUC, 0.79), alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (AUC, 0.74), and chitinase-3-like protein 2 (CHI3L2; AUC, 0.73). Of these, GPNMB, GPC1, and CHI3L2 were significantly correlated to prognostic progression rate.Conclusion: This study demonstrated that CSF levels of neuroinflammation and glycosylation-related proteins were significantly correlated with prospective progression rates in patients with ALS. These proteins could be useful prognostic biomarkers for ALS.Keywords
This publication has 51 references indexed in Scilit:
- Chronically activated microglia in ALS gradually lose their immune functions and develop unconventional proteomeGlia, 2024
- Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral SclerosisJAMA Neurology, 2022
- Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALSJournal of Molecular Neuroscience, 2019
- Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosisActa Neuropathologica, 2019
- Exploring Cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral SclerosisMolecular Neurobiology, 2019
- Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosisAnnals of Neurology, 2018
- CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosisJournal of Neurology, 2018
- Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosisJournal of Neurology, 2016
- CSF markers in amyotrophic lateral sclerosisJournal of Neural Transmission, 2012
- Slit and glypican‐1 mRNAs are coexpressed in the reactive astrocytes of the injured adult brainGlia, 2003